Abstract
Human mobility patterns changed greatly due to the COVID-19 pandemic. Despite many analyses investigating general mobility trends, there has been less work characterising changes in mobility on a fine spatial scale and developing frameworks to model these changes. We analyse zip code-level mobility data from 26 US cities between February 2 – August 31, 2020. We use Bayesian models to characterise the initial decrease in mobility and mobility patterns between June - August at this fine spatial scale. There were similar temporal trends across cities but large variations in the magnitude of mobility reductions. Long-distance routes and higher-income subscribers, but not age, were associated with greater mobility reductions. At the city level, mobility rates around early April, when mobility was lowest, and over summer showed little association with non-pharmaceutical interventions or case rates. Changes in mobility patterns lasted until the end of the study period, despite overall numbers of trips recovering to near baseline levels in many cities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AW is supported by a Career Award at the Scientific Interface from the Burroughs Wellcome Fund. RA, KLS, CS and AW are all supported by National Institute of Health Directors New Innovator Award, grant number DP2LM013102-0. RA, KLS, CS, DATC, and AW are also supported by the National Institute of Allergy and Infectious Diseases (1R01A1160780-01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study is approved by the Institutional Review Board of Johns Hopkins Bloomberg School of Public Health (IRB00015892). The consent for participants is waived by the Institutional Review Board of Johns Hopkins Bloomberg School of Public Health.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data on mobile phone provider subscriber movement and demographics is confidential and cannot be shared. Mock data and code to replicate the analysis using this data is available at https://github.com/rarambepola/US-cities-COVID-mobility. All other data used has been referenced and is publicly available.
